Prices delayed by at least 15 minutes | Print


NEVRO Corp (NVRO)

Sell: $12|Buy: $13.41|Change: 0.25 (-2.03%)

Open 

$12.3


Previous close 

$12.32


Trade high 

$12.56


Volume 

385,671


Year high 

$38.59


Year low 

$12.05


Dividend yield 

-


Market capitalisation 

$442.74 mn


P/E ratio 

147.06


ISIN 

US64157F1030


This share can be held in a Dealing accountISALifetime ISAJISASIPP

Share price

Performance 19/04/2024

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann


Total return (%)
NEVRO Corp- 2.03
More...

Company profile

Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain. Senza generates electrical impulses to relieve pain. The system is implanted by physicians and controlled by patients. It consists of leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician laptop programmer, a patient remote control, and a mobile charger. The company generates the majority of its revenue in the United States.

Sector 

Healthcare


AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2024 AJ Bell. All rights reserved.